Help
Home
Search the Forum
You are Here :
Forum
Jobs
Singapore, Malaysia
AYP Associates Pte Ltd Singapore : Medical Advisor
Ask Question / Post resume
Post a reply to the thread:
AYP Associates Pte Ltd Singapore : Medical Advisor
Your Message
Your Username:
Click here to log in
Notes:-
1) You can copy and paste your full resume in the box below.
2) Or you can ask your question. We try to answer, as far as possible.
Title:
[QUOTE=Guest;232236]CURRICULUM VITAE [b][b]PERSONAL DETAILS [/b] [/b]: First Name Sergio Surname Palmeri Specialty Oncology Nationality Italy Gender Male Date of birth 04/May/1950 Marital Status married Email sergiopalmeri AT alice.it [b][b]MEDICAL AND ACADEMIC DEGREES [/b] [/b]: Degree Subject Medical School Year of Graduation Medical Doctor Yes, University of Palermo Italy 1975 1. Specialist Cardiovascular diseases University of Palermo Italy 1978 2. Specialist Oncology University of Genoa ITALY 1982 [b][b]MEDICAL COUNCIL REGISTRATION [/b] [/b]: General Medical Council National Medical Chamber Other “Italian Medical Order” n° 5722 Since 1/March/1976 [b][b]LANGUAGES [/b] [/b]: Language Level of language (Native – Fluent – Good – Basic) Italian Native English Fluent [b][b]PROFESSIONAL EMPLOYMENT HISTORY [/b] [/b]: [b][b]CURRENT POSITION [/b] [/b]: from 1/July/2012-today Private practice as Medical Oncologist Since the 1st/July/2012 ,after my volunteer retirement, I practice as a private Medical Oncologist. Under this position I see all type of solid tumors deciding on my own the initial assessment, the medical therapy and, when needed consulting my colleagues either Radiotherapist or surgeons in order to plan a multidisciplinary approach to the individual patient. At present when a patient of mine require to be admitted to an oncology ward (to receive chemotherapy, supportive care or combination radio-chemo treatment) I refere him/her to two private Hospital (part of our NHS) of the town where, in accord with my colleagues, I can see them with in order of avoiding any care discontinuity. [b][b]PREVIOUS EMPLOYMENT [/b] [/b]: 1/Nov/1991 30/June/2012 University Hospital (Azienda Ospedaliera Universitaria Policlinico), Palermo Italy. Associate Professor of Medical Oncology (& senior Medical Oncologist consultant) (Please note this position was on hold during my service at EMA) The University Hospital of Palermo is a large general Hospital, serving a population of about 750.000 with almost, all specialties, 750 beds, completely dedicated to University teaching (MD & health care professionals). The Oncology Department, where I was working in, includes Surgical Oncology, General Surgery, Plastic and Reconstructive Surgery, Medical Oncology, Hematology, Endoscopy. The Medical Oncology Unit works both on an out- and in-patients basis. My personal professional experience includes the two species of patients but lastly, since the 1st/Nov/2005, when I was appointed as responsible of the “Innovative Cancer therapy Unit”, through the 30th/June/2012 I was mainly working on an out-patient basis. I was in charge of first seeing the new patients establishing the staging procedures and treatment plans or the follow-up strategies, as needed. I was personally seeing a mean of 50 pts/week (approximately 5 were new). When appropriated I personally did paracentesis and pleurocentesis. Usually I was on-call once a month. All the therapeutic decisions were taken on my direct responsibility after a deep discussion with all my co-workers. I was also on charge of establishing all the scientific research lines, both clinical (e.g. panitumumab in lung cancer, everolimus as II line in HCC). At least once a month we had a multidisciplinary discussion with our pathologist, surgeon and radiologist in order to plan the correct approach to complex clinical situations. Between my duties there was also the supervision of younger colleagues and trainees. My clinical experience includes all type of solid cancer but I was manly seeing GI (mostly colon), breast, lung, prostate, CUP and renal cancers. My police was to avoid any undue overtreatment so, when indicated, I decided to give to the patient all needed supportive/palliative care. This was done either within our department or, in case of bed lack, referring the patient to one of the town Hospices. I have also a good clinical experience in the treatment of hematological malignancies (mainly lymphomas) because from 1/March/1996 to 22/June/2006 I was assigned to the Hematology (in the same University Hospital) ward where, while continuing to see and treat solid cancers I had the opportunity of expanding my clinical experience also in this subspecialty. During this period my knowledge on all the oncology emergencies received a further impulse also because it often happened to be on call and have to decide the treatment or further hospitalization. [b][b]October/1/2006–June/30/2007 [/b] [/b]: (please note during this period of time my position as Ass Prof was on hold) European Medicine Agency (EMA) London UK “Oncology Therapeutic Group Leader” (after a public European Union wide open competition). During this very intense working period I was leading and coordinating, in London UK, a group of MDs & Science Graduates with the task of handling the applications of new anticancer drugs in the EU. I was requested by the Agency to use all my vast clinical experience in evaluating and discriminating all the clinical studies supporting the requests of new anticancer drug registration. In particular, during the registration process, the task was to act with equilibrium keeping always in mind the Agency’s Mission Statement, the interest of patients and those of applicant Pharmaceutical Companies. During that time my group was managing the applications of almost completely new anticancer drugs as e.g. tarceva, imatinib, nilotinib, thalidomide, lenalidomide etc... I also promoted, within the Agency, key training initiatives including seminaries on Medical Oncology, meeting a great interest inside the Agency. Another important accomplished result was the fostering the cooperation between the Agency and the U.S. FDA. I also contributed to international meeting as invited speaker (TAT 2007 conference in Amsterdam, 1st BDA Alpine Meeting Innsbruck 2007) and presenting a poster at ASCO 2007. Actually I can say that this period of my life was a very fruitful one . I understood better all the difficulties that the pharmaceutical companies have to overcome during the registration process of a new anticancer product (especially those very expensive for the community). Another important key point acquired was the understanding of all the subtle and “political reasons” underlying all the CHMP decisions. (please note that after the 30/June/2007 I took again service at the University Hospital of Palermo) 1/Aug/1980 - 30/Oct/1991 University Hospital (Azienda Ospedaliera Universitaria Policlinico), Palermo Italy. [b][b]CONGRESSES, CONFERENCES & Scientific Activities [/b] [/b]: (last 5 years) [b][b]“The role of biomarkers in the regulatory process” 5th International Symposium on Targeted Anticancer Therapies. Amsterdam, The Netherlands, March 8-10, 2007 – Plenary session [/b] [/b]: methodological and regulatory issues in oncology drug development “Clinical surrogate endpoints- Clinical benefit scores” 3rd Alpine Meeting-Strategies for harmonization of next generation oncology drug development Innsbruck, March 14-16, 2007 – Clinical trial design issues. [b][b]“Capecitabine or folinic acid/fluorouracil i.v. bolus plus eloxatin evaluation (COFFE trial) in metastatic colorectal carcinoma (MCRC) [/b] [/b]: final results of the Southern Italy Cooperative Oncology Group (SICOG) 0401” 9th National Congress of Medical Oncology,12-15 October 2007, Ann Oncol vol 18, suppl 11, A65 [b][b]“Dose-dense chemotherapy and the onset of anemia [/b] [/b]: new insights” 9th National Congress of Medical Oncology,12-15 October 2007, Ann Oncol vol 18, suppl 11, D46 “Cooperation between Academia and Regulatory Agencies; the recent Italian experiences in clinical oncology”4th Alpine Meeting- Meeting the challenges of oncology drug development, Innsbruck, October 15-17, 2008 [b][b]“Randomized comparison of capecitabine versus fluorouracil/leucovorin in combination with oxaliplatin in metastatic colorectal cancer patients [/b] [/b]: Southern Italy Cooperative Oncology Group trial 0401” 2008 Gastrointestinal Cancers Symposium, abs344 “Serum HER-2/neu (s-HER2) levels evaluation in breast cancer (BC) patients (PTS)” [b][b]10th National Congress of Medical Oncology, 11-14 October 2008 [/b] [/b]: Verona; abs M24 [b][b]“Final results of a phase II trial of a weekly (W) poly-chemotherapy (CT) with cisplatin (CDDP), epirubicin (EPI), fluorouracil (5FU), folinic acid (FA) and G-CSF for the treatment of locally advanced (LA) or metastatic (M) gastro esophageal (GE) and gastric (G) cancer (C) patients (pts)” Gastrointestinal Cancers Symposium, 15-17 January 2009 [/b] [/b]: San Francisco, CA; [b][b]“Bevacizumab (Bev) with irinotecan (IRI), folinic acid (FA), and 5-fluorouracil (FU) every 2 weeks (BIFF regimen) as first-line treatment for metastatic colorectal cancer (MCRC) patients (pts) [/b] [/b]: an [b][b]observational study of the Southern Italy Cooperative Oncology Group (SICOG)” Gastrointestinal Cancers Symposium, 15-17 January 2009 [/b] [/b]: San Francisco, CA; abs n. 408 [b]TEACHING RESPONSIBILITIES [/b]: [b]Part I [/b]: teaching activity for medical students & young MDs Since August 1980 through October 1991 as researcher with tenure (assistant professor) of the Faculty of Medicine of the University of Palermo) teaching and examinations duties in the field of antineoplastic chemotherapy within the official course of pharmacology for medical students. [b]From November 1991 (after a nationwide open competition) through June 2012, I have been continuously holding, as Associate Professor, the chair of Medical Oncology at the same University having within my duties [/b]: a) the official course of Medical Oncology lessons for medical students (both “ex cathedra” and at the patient’s bed side; b) regular students examinations (at least 4 session/y); c) to guide and follow students up in preparing their theses for the final dissertations before graduating; d) official component of the Medicine graduating commissions; e) seminars and special classes for post-grad students within a number of medical specialization schools (e.g. Medical Oncology, Internal Medicine, Pathology, Hematology); f) theoretical and practical tutorial activity for young MDs to teach them how to “know to be” and what a modern and up-to-date MD has to “know to do”; g) to guide and follow young MDs up in preparing their theses for the final dissertations at the end of the specialization course; [b]Part II [/b]: teaching activity for health professionals - From November 1992 through June 2012 I have hold the official Medical Oncology courses for nurses within the “Nurses school” at the Palermo Civic Hospital and at the University Hospital. - From the Academic Year 1998/1999 through 2005/2006 I have held the official Medical Oncology courses for “Rehabilitation Physiotherapist” at the Palermo University Hospital. - For both type of health professional students my duties have been including examinations and tutorial activity for preparation and writing their final dissertations - From the Academic Year 2001/2002 through 2005/2006 I have hold the class on” The solid tumors Bio-characterization & Bio-technology in the solid tumors therapy” within the official Course for graduating (PhD) students in “Bio-technology”. [b]Part III [/b]: teaching activity for MDs, post-grad health & Science professionals and statisticians - From 2006 through June 2012 Director of the “University Master in Design and Conduct of Clinical Trials in Humans” (of which I have been the founder). [b]RESEARCH AND PUBLICATIONS [/b]: [b]Although my personal clinical experience includes the medical management of all solid tumors my principal fields of scientific interest are [/b]: the medical treatment of GI cancer with a special interest in colorectal, breast, lung cancer, targeted therapies, new anticancer drugs, management of cancer drugs side effects (special interest in febrile neutropenia management), unknown primary cancers, clinical trials in Medical Oncology, patient-physician relationship/quality of life issues. Author of #163 full scientific papers (#92 indexed with ISI IF, list available upon request). [b]PROFESSIONAL SOCIETY MEMBERSHIPS [/b]: ESMO (active member) AIOM (active member) ASCO (past member) [b]PERSONAL INTERESTS [/b]: During my spare time I like reading, listening to the classic music and walking in the countryside. My preferred sport is football.[/QUOTE]
